Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company’s web site at http://www.gentium.com.
- 18 years ago
QualityStocks
Gentium S.p.A. (NASDAQ: GENT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Why TruGolf Holdings Inc. (NASDAQ: TRUG) Is ‘One to Watch’
TruGolf (NASDAQ: TRUG) is pursuing a strategic expansion into blockchain-based financial infrastructure through its pending…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Brings Interactive Experiences to Major Sports and Entertainment Audiences
Versus Systems (NASDAQ: VS) uses gamification and audience engagement technology to help brands, sports teams,…
-
QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Builds Momentum with Potential 1,500-Home Pipeline
BOXABL (NASDAQ: BXBL) has signed a multiyear purchase agreement with LC Vegas Acquisitions, LLC for…